Evidence map›Paper›PMID 19087274›Full record

ArticleBreast cancer research : BCR2008

Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.

Changhua Zhou, Ashley M Nitschke, Wei Xiong, Qiang Zhang, Yan Tang, Michael Bloch, Steven Elliott, Yun Zhu, Lindsey Bazzone, David Yu and 9 more

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 104 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Impact of ERK5 on the Hallmarks of Cancer.International journal of molecular sciences · 2019
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Oncogenic signaling of MEK5-ERK5.Cancer letters · 2017
    Review
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Changhua ZhouDepartment of Chemistry, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Ashley M Nitschke
Wei Xiong
Qiang Zhang
Yan Tang
Michael Bloch
Steven Elliott
Yun Zhu
Lindsey Bazzone
David Yu
Christopher B Weldon
Rachel Schiff
John A McLachlan
Barbara S Beckman
Thomas E Wiese
Kenneth P Nephew
Bin Shan
Matthew E Burow
Guangdi Wang
Tulane University · USXavier University of Louisiana · USBoston Children's Hospital · USBaylor College of Medicine · USIndiana University Bloomington · US

Funding

TUMOR SUPPRESSOR GENES IN BREAST CANCER DEVELOPMENTP50CA058183 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI OSBORNE, C KENT · 1992 to 2012
$30.9M
UNCOVERING THE MECHANISMS OF OSTEOSARCOMA METASTASIS SUPPRESSION BY MTBPP20RR020152 · NCRR · TULANE UNIVERSITY OF LOUISIANA · PI YOU, ZONGBING · 2004 to 2011
$17.0M
P13K/AKT crosstalk with ER-signaling and cell survivalR01DK059389 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI BUROW, MATTHEW E. · 2003 to 2008
$1.8M
NCI NIH HHS P50 CA058183NCI NIH HHS P50 CA58183NCRR NIH HHS P20 RR020152NIDDK NIH HHS DK059389NIDDK NIH HHS R01 DK059389
6 · The paper itself

Abstract

introductionDespite intensive study of the mechanisms of chemotherapeutic drug resistance in human breast cancer, few reports have systematically investigated the mechanisms that underlie resistance to the chemotherapy-sensitizing agent tumor necrosis factor (TNF)-alpha. Additionally, the relationship between TNF-alpha resistance mediated by MEK5/Erk5 signaling and epithelial-mesenchymal transition (EMT), a process associated with promotion of invasion, metastasis, and recurrence in breast cancer, has not previously been investigated.

methodsTo compare differences in the proteome of the TNF-alpha resistant MCF-7 breast cancer cell line MCF-7-MEK5 (in which TNF-alpha resistance is mediated by MEK5/Erk5 signaling) and its parental TNF-a sensitive MCF-7 cell line MCF-7-VEC, two-dimensional gel electrophoresis and high performance capillary liquid chromatography coupled with tandem mass spectrometry approaches were used. Differential protein expression was verified at the transcriptional level using RT-PCR assays. An EMT phenotype was confirmed using immunofluorescence staining and gene expression analyses. A short hairpin RNA strategy targeting Erk5 was utilized to investigate the requirement for the MEK/Erk5 pathway in EMT.

resultsProteomic analyses and PCR assays were used to identify and confirm differential expression of proteins. In MCF-7-MEK5 versus MCF-7-VEC cells, vimentin (VIM), glutathione-S-transferase P (GSTP1), and creatine kinase B-type (CKB) were upregulated, and keratin 8 (KRT8), keratin 19 (KRT19) and glutathione-S-transferase Mu 3 (GSTM3) were downregulated. Morphology and immunofluorescence staining for E-cadherin and vimentin revealed an EMT phenotype in the MCF-7-MEK5 cells. Furthermore, EMT regulatory genes SNAI2 (slug), ZEB1 (delta-EF1), and N-cadherin (CDH2) were upregulated, whereas E-cadherin (CDH1) was downregulated in MCF-7-MEK5 cells versus MCF-7-VEC cells. RNA interference targeting of Erk5 reversed MEK5-mediated EMT gene expression.

conclusionsThis study demonstrates that MEK5 over-expression promotes a TNF-alpha resistance phenotype associated with distinct proteomic changes (upregulation of VIM/vim, GSTP1/gstp1, and CKB/ckb; and downregulation of KRT8/krt8, KRT19/krt19, and GSTM3/gstm3). We further demonstrate that MEK5-mediated progression to an EMT phenotype is dependent upon intact Erk5 and associated with upregulation of SNAI2 and ZEB1 expression.

Indexed as

Drug Resistance, NeoplasmProteomicsBiomarkers, TumorBlotting, WesternBreast NeoplasmsCell SurvivalChromatography, LiquidElectrophoresis, Gel, Two-DimensionalEpitheliumFluorescent Antibody TechniqueGene Expression ProfilingHumansMAP Kinase Kinase 5MesodermMitogen-Activated Protein Kinase 7PhenotypeBiomarkers, TumorMAP2K5 protein, humanMAP Kinase Kinase 5Mitogen-Activated Protein Kinase 7RNA, MessengerRNA, Small InterferingTumor Necrosis Factor-alpha

Identifiers

PMID19087274
PMCPMC2656902
OpenAlexW2091475315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.